Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-28T07:02:39.006Z Has data issue: false hasContentIssue false
  • English
  • Français

Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene

Published online by Cambridge University Press:  19 October 2015

Daniel Camilo Aguirre-Acevedo ,
Fabian Jaimes-Barragán ,
Eliana Henao ,
Victoria Tirado ,
Claudia Muñoz ,
Eric M. Reiman ,
Pierre N. Tariot ,
Jessica B. Langbaum  and
Francisco Lopera Open the ORCID record for Francisco Lopera [Opens in a new window]
Daniel Camilo Aguirre-Acevedo*
Affiliation:
Grupo de Neurociencias de Antioquia, Grupo Académico de Epidemiología Clínica, School of Medicine, Medical Research Institute, University of Antioquia, Medellín, Colombia
Fabian Jaimes-Barragán
Affiliation:
Grupo Académico de Epidemiología Clínica and Research Unit, Hospital Pablo Tobón Uribe, School of Medicine, University of Antioquia, Hospital Pablo Tobón Uribe, Medellín, Colombia
Eliana Henao
Affiliation:
Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
Victoria Tirado
Affiliation:
Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
Claudia Muñoz
Affiliation:
Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
Eric M. Reiman
Affiliation:
Banner Alzheimer's Institute, Arizona, USA
Pierre N. Tariot
Affiliation:
Banner Alzheimer's Institute, Arizona, USA
Jessica B. Langbaum
Affiliation:
Banner Alzheimer's Institute, Arizona, USA
Francisco Lopera
Affiliation:
Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
*
Correspondence should be addressed to: Dr Daniel Camilo Aguirre-Acevedo, Sede de Investigación Universitaria – SIU, Calle 62, No. 52–59, Medellín, Colombia. Phone: +574-219-6090; Fax: +574-219-6444. Email: daniel.aguirre@udea.edu.co
Get access

Abstract

Background:

This study aimed to determine Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Assessment Battery total score diagnostic accuracy in the diagnosis of mild cognitive impairment (MCI) and dementia in familial Alzheimer's disease (FAD) with E280A mutation on presenilin-1 gene (PSEN1).

Methods:

A cross-sectional study was conducted in a cohort of PSEN1 E280A carriers and non-carriers assessed between January 1995 and February 2013. During the first neuropsychological assessment, 76 were having dementia, 46 had MCI, and 1,576 were asymptomatic. CERAD cut-off points were established for MCI and dementia using a Receiver Operating Characteristics (ROC) analysis, and were further analyzed according to education level in two groups: low education level (eight years or less), and high education level (over eight years).

Results:

The area under curve–ROC CERAD total score for dementia was 0.994 (95% CI = 0.989–0.999), and that for MCI was 0.862 (95% CI = 0.816–0.908). The dementia diagnosis cut-off point for the low education group was 54, (98.4% sensitivity, 92.6% specificity), and that for the high education group was 67 (100% sensitivity, 94.1% specificity). The MCI diagnosis cut-off point for the low education group was 66 (91.2% sensitivity, 56.4% specificity), and that for the high education group was 72 (91.7% sensitivity, 76.3% specificity).

Conclusions:

The CERAD total score is a useful screening tool for dementia and MCI in a population at risk of FAD.

Keywords

Alzheimer's diseaseCERADmild cognitive impairmentvaliditysensitivity
Type
Research Article
Information
International Psychogeriatrics , Volume 28 , Issue 3 , March 2016 , pp. 503 - 510
Copyright
Copyright © International Psychogeriatric Association 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Acosta-Baena, N. et al. (2011). Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurology, 10, 213–220.Google Scholar
Aguirre-Acevedo, D. et al. (2007). Validity and reliability of the CERAD-Col neuropsychological battery. Revista de Neurología, 45, 655–660.Google Scholar
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association Google Scholar
Ardila, A. et al. (2000). Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280 A single presenilin-1 mutation. Archives of Clinical Neuropsychology, 15, 515–528.Google Scholar
Barth, S., Schönknecht, P., Pantel, J. and Schröder, J. (2005). Mild cognitive impairment and Alzheimer's disease: an investigation of the CERAD-NP test battery. Fortschritte der Neurologie-Psychiatrie, 73, 568–576.Google Scholar
Chandler, M. J. et al. (2005). A total score for the CERAD neuropsychological battery. Neurology, 65, 102–106.Google Scholar
Cornejo, W., Lopera, R. F., Uribe, C. S. and Salinas, M. (1987). Description of a family with presenile dementia type Alzheimer. Acta Médica Colombiana, 12, 55–61.Google Scholar
Fillenbaum, G. G. et al. (2008). Consortium to Establish a Registry for Alzheimer's disease (CERAD): the first twenty years. Alzheimer's and Dementia, 4, 96–109.Google Scholar
Hallikainen, I. et al. (2013). Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study. International Psychogeriatrics, 25, 1335–1344.Google Scholar
Han, J. Y. et al. (2014). A normative study of total scores of the CERAD neuropsychological assessment battery in an educationally diverse elderly population. International Psychogeriatrics, 26, 1897–1904.Google Scholar
Larner, A. J. and Doran, M. (2006). Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. Journal of Neurology, 253, 139–158.Google Scholar
Lee, J. H. et al. (2002). Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's disease assessment packet (CERAD-K): clinical and neuropsychological assessment batteries. The Journal of Gerontology. Series B Psychological Sciences and Social Sciences, 57, P47–P53.Google Scholar
Lemere, C. A. et al. (1996). The E280 A presenilin 1 Alzheimer's mutation produces increased a beta 42 deposition and severe cerebellar pathology. Nature Medicine, 2, 1146–1150.Google Scholar
Lopera, F. et al. (1997). Clinical features of early-onset Alzheimer's disease in a large kindred with an E280 A presenilin-1 mutation. JAMA, 277, 793–799.Google Scholar
Mckhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, 939–944 Google Scholar
Morris, J. C. (1993). The clinical dementia rating (CDR): current version and scoring rules. Neurology, 43, 2412–2414.CrossRefGoogle ScholarPubMed
Morris, J. C. et al. (1989). The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159–1165.Google Scholar
Morris, M. C., Evans, D. A., Hebert, l. E. and Bienias, J. L. (1999). Methodological issues in the study of cognitive decline. American Journal of Epidemiology, 149, 789–793.CrossRefGoogle Scholar
Paajanen, T. et al. (2010). CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study. Journal of Alzheimer's Disease, 22, 1089–1097.Google Scholar
Pastor, P. et al. (2003). Apolipoprotein Epsilon 4 modifies Alzheimer's disease onset in an E280 A PS1 kindred. Annals of Neurology, 54, 163–169.Google Scholar
Petersen, R. C. (2009). Early diagnosis of Alzheimer's disease: is MCI too late? Current Alzheimer's Research, 6, 324–330.Google Scholar
Petersen, R. C. et al. (2001). Current concepts in mild cognitive impairment. Archives of Neurology, 58, 1985–1992.Google Scholar
Rossetti, H. C., Munro-Cullum, C., Hynan, L. S. and Lacritz, L. H. (2010). The CERAD neuropsychologic battery total score and the progression of Alzheimer's disease. Alzheimer's Disease and Associated Disorders, 24, 138–142.Google Scholar
Seo, E. H. et al. (2010). Total scores of the CERAD neuropsychological assessment battery: validation for mild cognitive impairment and dementia patients with diverse etiologies. American Journal of Geriatric Psychiatry, 18, 801–809.Google Scholar
Sotaniemi, M. et al. (2012). CERAD-neuropsychological battery in screening mild Alzheimer's disease. Acta Neurologica Scandinavica, 125, 16–23.Google Scholar
Unverzagt, F. W. et al. (1999). Clinical utility of CERAD neuropsychological battery in elderly Jamaicans. Journal of the International Neuropsychological Society, 5, 255–259.Google Scholar
Wolfsgruber, S. et al. (2014). The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy. American Journal of Geriatric Psychiatry, 22, 1017–1028.Google Scholar
Supplementary material: File

Aguirre-Acevedo supplementary material S1

Supplementary Table and Figure

Download Aguirre-Acevedo supplementary material S1(File)
File 144.5 KB